

Technology Advisory Committee B Interests Register

Topic: [Rozanolixizumab for treating antibody-positive generalised myasthenia gravis \[ID5092\]](#)

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
David McAllister	TAC B Committee Member	Non-Financial Professional interests	<p>BI and UCB - use individual-level trial data provided by both sponsors via the Vivli platform in my academic research.</p> <p>Conducting academic research using data provided by sponsors and/or their competitors via a trial data sharing platform (Vivli).</p>	<p>23/01/2026</p> <p>29/07/2024</p>	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal.
Alistair Patton	TAC B Committee Member	Non-Financial Professional interests	Alistair attended UCB Pharma sponsored conferences for paediatric epilepsy but did not receive an honorarium as he was only an attendee not a speaker	26/07/2024	It was agreed that Alistair's declaration would not prevent him from participating in discussions on this appraisal.
Dr Maria Isabel Leite	Clinical Expert	Non-Financial Professional interests	Oct/2022 to 2023: served on advisory and educational boards and acted as a speaker at UCB organised and sponsored educational events.	14/08/2024	It was agreed that Dr Leite's declaration would not prevent her from

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
			<p>These advisory boards have focussed on the management and treatment of myasthenia gravis and UCB treatments under development for the treatment of myasthenia gravis (zilucoplan and rozanolixizumab).</p> <p>The contracted parties for the above were UCB and Oxford University.</p> <p>Oct/2022 to 2023: have served on advisory board and acted as speaker at an Argenx organised and sponsored educational event.</p> <p>Those activities have focussed on the management of myasthenia gravis, in general, and on medical treatments, including that developed for generalised myasthenia gravis by Argenx (efgartigimod).</p>		<p>providing expert advice to the committee.</p>

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
			<p>The contracted parties for the above were Argenx and Oxford University</p> <p>Oct/2022 to 2023: a member of the steering committee for a clinical trial developed by Horizon for generalised myasthenia gravis (MINT) and acted as chairman in an educational session organised and sponsored by Horizon.</p> <p>The contracted parties for the above were Horizon and Oxford University</p>		
Dr Jennifer Spillane	Clinical Expert	Direct – Financial	<p>Dr Spillane have received speakers fees and travel support from argenx.</p> <p>Dr Spillane has taken part in consultancy discussions with UCB (discussing published papers and treatment landscape for MG)</p> <p>Dr Spillane is in the process of submitting a paper describing the</p>	14/08/2024	It was agreed that Dr Spillane's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest Declared	Comments
			UK experience of the Early Access to Medicine Scheme for Efgartigimod – note not submitted as of yet – still in progress		